https://www.selleckchem.com/pr....oducts/wnt-agonist-1
Amongst survivors, a major IMACS response was recorded in 54.5% adults and 100% children. 30% suffered from moderate to severe disability and 16.7% experienced relapses. Overall, two-thirds accrued the composite adverse outcome.In a multivariate analysis, older age and anti-MDA5 predicted mortality. Arthritis, rash, and positive ANA reduced and anti-MDA5 increased the risk for the composite adverse outcome. Indian patients with IIM suffer high early mortality attributable to infection, cancer and RP-ILD, calling for high vigilance
Like
Comment
Share
